Clinical Trial

Pharmacological Inhibition of Lactation After 16 to 20 Week Abortion

Recruiting Phase 4
View on ClinicalTrials.gov →
Record status
This record was last updated May 29, 2024 (before its estimated June 30, 2024 completion). Its status may not reflect the trial's current state.
Summary
The goal of this clinical trial is to compare breast symptoms (lactation, engorgement, etc) of individuals who undergo a procedure for second trimester of pregnancy loss between 16 weeks and 20 weeks gestational age. The participants will be randomly placed in two groups, one with a placebo tablet and one with medication called "cabergoline" which are taken immediately after their procedure. Researchers will compare groups to see if there are any significant differences in breast symptoms.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2023-11-07; most recent amendment 2026-02-10.
Status change: Recruiting → Completed 2026-02-10
Status change: Not Yet Recruiting → Recruiting 2024-03-07
Trial Details
NCT Number NCT06123026
Lead Sponsor Northwestern University
Conditions Lactation Suppressed, Second Trimester Abortion
Enrollment 200 participants
Start Date 2023-12-18
Primary Completion 2024-06-30 (estimated)
Study Completion 2024-06-30 (estimated)
Updated on ClinicalTrials.gov 2024-05-29